Teva Says Top-Line Results from Second Phase III Study of Armodafinil Failed to Meet Primary, Secondary Endpoints
Posted on January 23, 2013 at 09:46 AM EST
Teva Pharmaceutical Industries Ltd. today announced top-line results of its Phase III clinical program for armodafinil (NUVIGIL®) as adjunct therapy in adults with major depression associated with bipolar 1 disorder. While study 3072 demonstrated a numerical improvement, it did not reach statistical significance in meeting its primary endpoint -- to